Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 09, 2015 06:30 ET | Source: CytoDyn

CytoDyn Cleared by FDA to Start Phase 3 of First Injectable Antibody for HIV

VANCOUVER, Wash., June 9, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating human immunodeficiency virus (HIV)...
May 04, 2015 16:01 ET | Source: CytoDyn

CytoDyn Submits Phase 3 Protocol to FDA After Agreement on Protocol Synopsis

Six Months of Monotherapy With PRO 140 Has Been Effective for HIV Patients in Phase 2b Study Conference Call Scheduled for May 5 at 1:00 p.m. PT / 4:00 p.m. ET VANCOUVER, Wash., May 4,...
February 03, 2015 08:45 ET | Source: CytoDyn

CytoDyn Concludes Phase 2b Study With 98% Success With 4 Weeks of Monotherapy - Many HIV Patients in Extension Study With Some Approaching 6 Months

VANCOUVER, Wash., Feb. 3, 2015 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
November 24, 2014 08:00 ET | Source: CytoDyn

CytoDyn Information Now Available Through S&P Capital IQ Corporation Records Program

VANCOUVER, Wash., Nov. 24, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
October 13, 2014 08:00 ET | Source: CytoDyn

CytoDyn Announces 100% Success With PRO 140 in Four-Week Monotherapy Clinical Trial

VANCOUVER, Washington, Oct. 13, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
October 10, 2014 16:26 ET | Source: CytoDyn

CytoDyn Announces Investment Community Call to Discuss Results From Its Treatment Substitution Clinical Trial in Patients With HIV

VANCOUVER, Wash., Oct. 10, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
October 01, 2014 15:43 ET | Source: CytoDyn

CytoDyn Appoints Carl Dockery to Board of Directors

VANCOUVER, Wash., Oct. 1, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
August 15, 2014 15:06 ET | Source: CytoDyn

CytoDyn Announces Webcast for Annual Shareholder Meeting

VANCOUVER, Wash., Aug. 15, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human immunodeficiency...
July 31, 2014 08:20 ET | Source: CytoDyn

CytoDyn Announces Positive Interim Results From Its Treatment Substitution Study in Patients With HIV

VANCOUVER, Wash., July 31, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...
July 30, 2014 21:51 ET | Source: CytoDyn

CytoDyn Announces Investment Community Call to Discuss Interim Results From Its Treatment Substitution Study in Patients With HIV

VANCOUVER, Wash., July 30, 2014 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB:CYDY), a biotechnology company focused on the development of new therapies for combating infection with human...